Renal Transplantation and Raltegravir in HIV-Infected Patients

Phase 3 Completed 27 enrolled ANRS, Emerging Infectious Diseases Merck Sharp & Dohme LLC · collab

NaSingle-groupOpen-labelTreatment

Summary

The aim of this study is to evaluate the incidence of acute renal graft rejection 6 months after transplantation in HIV-infected patients under three antiretroviral drugs regimen including Raltegravir.

Timeline

Start: 2011-12
Primary completion: 2015-11
Completion: 2015-11

Outcome

Met primary endpoint

paper estimated clinical acute rejection rate of 8% [95% confidence interval (CI) 2-24%] PMID 30688008 ↗

Publications

Results Matignon M, Lelievre JD, Lahiani A, Abbassi K, Desvaux D, Diallo A, Peraldi MN, Taburet AM, Saillard J, Delaugerre C, Costagliola D, Assoumou L, Grimbert P; ANRS 153 TREVE study group. Low incidence of acute rejection within 6 months of kidney transplantation in HIV-infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hepatites Virales (ANRS) 153 TREVE trial. HIV Med. 2019 Mar;20(3):202-213. doi: 10.1111/hiv.12700. Epub 2019 Jan 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Raltegravir	Other / unclassified	—	—